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Chinese University of Hong Kong, Shatin, Hong Kong, China
Chinese University of Hong Kong, Shatin, China
Background: The introduction of protein conjugate pneumo-
occal vaccine in many countries worldwide has led to capsular
eplacement in S. pneumoniae causing disease and nasopharyn-
eal carriage among children. Serotypes, such as serotypes 6C
nd 6D, were newly described in 2007 and 2009 respectively.
ctive surveillance on pneumococcal disease and carriage requires
rompt detection of changes in serotype distribution and identi-
cation of new serotypes. We describe the use of multiple PCRs
ased on the capsular loci to detect serotypes of 6A, B, C and D
rom pneumococci belonging to serogroup 6.
Methods: Serotypes of S. pneumoniaewere identiﬁedusingmul-
iple multiplex PCRs for determination of 40 serotypes according
o the CDC protocol. This protocol only typed serogroup 6 strains
nto 6C and non-6C serotypes. Strains belonging to serogroup 6
ere further typed into 6A, 6B, 6C and 6D serotypes based on
combination of three PCRs, using speciﬁc primers as described
1,2]. Primers that differentiate serotypes 6A and 6B were based
n single-nucleotide polymorphism in wciP of the capsular gene
oci between 6A and 6B (nucleotide 584a [195N] in 6B and 584g
195S] in 6A) that encodes rhamnosyl transferase. An additional
omologous recombination of wciNb resulting in the substitution
fwciN of 6A (wciN6A) is present in serotype 6Cwhilst ifwciNbwas
ntroduced into the serotype 6B operon it will be designated 6D [2].
Results: 242 isolates of S. pneumoniae belonging to serogroup 6
n a nasopharyngeal carriage study were further typed in 6A, B, C,
nd D serotypes using the above PCRs and comprised 58, 114, 60,
nd 6 isolates respectively. All strains, except four isolates (1.7%),
ere untypable and were discrepant to the results as used by the
DCPCRmethods todetermine6Candnon-6Cserotypes.Datawere
lso correlated to agglutination using serotype-speciﬁc anti-sera to
A, B and C.
[1]. Jin P et al., 2009. J. Infect. Dis. 200:1375-1380.
[2]. Jin P et al., 2009. J Clin Microbiol. 47:2470-2474.
Conclusion: The speciﬁc PCRs enable prompt identiﬁcation oferotypes6A,B,C, andD, andallowrapiddetectionofnewserotypes
elonging to serogroup 6 in pneumococcal surveillance studies.
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Extended-spectrum beta-lactamase positive rates for E. coli, K.
pneumoniae, andK.oxytoca in10Asiancountries -TESTprogram
from 2004-2011
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Background: ESBL-positive organisms continue to represent
therapeutic challenges for physicians as many currently marketed
antimicrobials are ineffective against these isolates. However, car-
bapenems and tigecycline are effective against many of these
organisms. As part of the Tigecycline Evaluation Surveillance Trial
(TEST), this report evaluates the incidence and susceptibility trends
of ESBL-positive isolates in 10 Asian countries from 2004-2011.
Methods: All clinical isolates identiﬁed as E. coli, K. pneumoniae,
orK. oxytocawere classiﬁedasESBL-positive or -negativeusingCLSI
criteria. MICs were determined at each participating laboratory by
CLSI broth microdilution.
Results: ESBL-positive rates averaged 28% for all Asia (see ﬁg-
ure). %Susceptible against ESBL-positive isolates were imipenem
99%, meropenem 98%, tigecycline 97%, amikacin 84%, piperacillin-
tazobactam 72%, minocycline 53%, and all others <40%.
* No ESBL+ isolates collected
Conclusion: ESBL-positive rates in E. coli and Klebsiella spp.
ranged from 0% in Indonesia to 48% in Thailand. Although other
studies have reported signiﬁcant increases in ESBL-positive rates in
Asia in the past few years, due to sampling variations the present
report cannot conﬁrm the high rates reported elsewhere. Tige-
cycline appears to have effective in vitro activity against ESBL+
organisms.
http://dx.doi.org/10.1016/j.ijid.2012.05.298
